Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial

Leo Sekine, Beatriz Arns, Bruna R. Fabro, Murillo M. Cipolatt, Rafael R.G. Machado, Edison L. Durigon, Edino Parolo, José Augusto S. Pellegrini, Marina V. Viana, Patrícia Schwarz, Thiago C. Lisboa, José Miguel S. Dora, Julia P. Portich, Alessandra A. Paz, Lucia Silla, Almeri M. Balsan, Felipe da-Silva Schirmer, Juliana P.M. Franz, Luciana M. da-Silveira, Raquel C. Breunig, Viviana Petersen, Monalisa Sosnoski, Nanci F. Mesquita, Fabiana Caroline Z. Volpato, Daniel Sganzerla, Maicon Falavigna, Regis G. Rosa, Alexandre P. Zavascki

Source: Eur Respir J, 59 (2) 2101471; 10.1183/13993003.01471-2021
Journal Issue: February

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Leo Sekine, Beatriz Arns, Bruna R. Fabro, Murillo M. Cipolatt, Rafael R.G. Machado, Edison L. Durigon, Edino Parolo, José Augusto S. Pellegrini, Marina V. Viana, Patrícia Schwarz, Thiago C. Lisboa, José Miguel S. Dora, Julia P. Portich, Alessandra A. Paz, Lucia Silla, Almeri M. Balsan, Felipe da-Silva Schirmer, Juliana P.M. Franz, Luciana M. da-Silveira, Raquel C. Breunig, Viviana Petersen, Monalisa Sosnoski, Nanci F. Mesquita, Fabiana Caroline Z. Volpato, Daniel Sganzerla, Maicon Falavigna, Regis G. Rosa, Alexandre P. Zavascki. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J, 59 (2) 2101471; 10.1183/13993003.01471-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Azithromycin for treatment of hospitalised COVID-19 patients: a randomised, multicentre, open-label clinical trial (DAWn-AZITHRO)
Source: ERJ Open Res, 8 (1) 00610-2021; 10.1183/23120541.00610-2021
Year: 2022



Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial
Source: Eur Respir J, 59 (1) 2100752; 10.1183/13993003.00752-2021
Year: 2022



Azithromycin and Hydroxychloroquine in hospitalized patients with confirmed SARS-CoV-2 infection - a randomized placebo-controlled trial (ProPAC-COVID Trial)
Source: Virtual Congress 2021 – COVID - 19 treatments
Year: 2021


PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017



Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19
Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19
Year: 2021



Umeclidinium in patients with COPD: a randomised, placebo-controlled study
Source: Eur Respir J 2014; 43: 72-81
Year: 2004



Roflumilast in Asian patients with COPD: A randomised placebo-controlled trial
Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Year: 2011

Effectiveness of influenza vaccination in asthmatic children: randomised, double-blind, placebo-controlled trial
Source: Eur Respir J 2002; 20: Suppl. 38, 146s
Year: 2002

Recombinant human deoxyribonuclease (rhDNase) for the treatment of acute asthma in children: a multicentre randomised double-blind clinical trial
Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up
Year: 2007


RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
Source: Virtual Congress 2021 – ALERT: COPD
Year: 2021



The early use of Antibiotics for at Risk CHildren with InfluEnza-like illness (ARCHIE): a double-blind randomised placebo-controlled trial
Source: Eur Respir J, 58 (4) 2002819; 10.1183/13993003.02819-2020
Year: 2021



Working memory training efficacy in COPD: the randomised, double-blind, placebo-controlled Cogtrain trial
Source: ERJ Open Res, 7 (4) 00475-2021; 10.1183/23120541.00475-2021
Year: 2021



Efficacy and costs of telehealth for the management of COPD: PROMETE II, a multicentre, randomized controlled trial
Source: International Congress 2017 – New trends in pulmonary rehabilitation and chronic care
Year: 2017



The role of phonophoresis in patients with COPD: a randomized clinical trial
Source: Virtual Congress 2020 – Clinical and basic pharmacology for COPD
Year: 2020


Chinese herbs in treatment of influenza: A multi-centre, randomized, double-blind, placebo-controlled trial
Source: Annual Congress 2010 - New aspects of treatment of lower respiratory tract infections
Year: 2010



Sedation for bronchoscopy in children: a prospective randomized double-blinded trial
Source: Virtual Congress 2021 – Posters in paediatric bronchology
Year: 2021


Methotrexate in treatment of severe difficult-to-treat asthma: randomized, double-blind, placebo-controlled study
Source: Annual Congress 2007 - Towards controlling severe asthma
Year: 2007


Antibiotic in non-purulent hospitalised-treated exacerbations of COPD: a randomised double-blind placebo-controlled trial
Source: International Congress 2019 – Airway infection in COPD
Year: 2019

Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial
Source: Eur Respir J, 56 (6) 2002808; 10.1183/13993003.02808-2020
Year: 2020